This site uses features not supported by Internet Explorer.

Belviq

Eisai, Inc. voluntarily withdrew the weight loss medication Belviq and Belviq XR (lorcaserin) from the U.S. market following a U.S. Food and Drug Administration request. Data showed that patients who had taken the drug as part of a large clinical safety trial showed an increased occurrence of cancer five years later. 7.7% of the lorcaserin subjects developed cancer, compared to the placebo group. Cancers observed included pancreatic, colorectal, and lung.

Landing Pages

Belviq 2800 draft v2 bt7xs6

CAMG has thousands of spots and infomercials that can be branded for your firm. Reach out to us for the latest creative offline and online examples*.
*Examples shown are not always current examples.

Request Samples

* These fields are required.

Media landscape article card pevnw7

The 2021 Media Landscape: What’s Ahead?

Plan your 2021 marketing with our exclusive media forecast.

Access here

Bosco shots r2qk f8t mb rw unsplash o3ibqc

CAMG Ethics White Paper

Get access to our exclusive White Paper and State Ethics Database.

Get it now!